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Abstract Vascular endothelial growth factor-A (VEGF-A)
has several isoforms, which differ in their capacity to bind
extracellular matrix proteins and also in their affinity for
VEGF receptors. Although the relative contribution of the
VEGF isoforms has been studied in tumor angiogenesis,
little is known about the mechanisms that regulate the
alternative splicing process. Here, we tested microenviron-
ment cues that might regulate VEGF alternative splicing.
To test this, we used endometrial cancer cells that produce
all VEGF isoforms as a model, and exposed them to
varying pH levels, hormones, glucose and CoCl2 (to mimic
hypoxia). Low pH had the most consistent effects in
inducing variations in VEGF splicing pattern (VEGF121
increased significantly, p<0.001, when compared to
VEGF145, 165 or 189). This was accompanied by activa-
tion of the p38 stress pathway and SR proteins (splicing
factors) expression and phosphorylation. SF2/ASF, SRp20
and SRp40 down-regulation by siRNA impaired the effects
of pH stimulation, blocking the shift in VEGF isoforms
production. Taken together, we show for the first time that
acidosis (low pH) regulates VEGF-A alternative splicing,
may be through p38 activation and suggest the possible SR





DMEM Dulbecco’s modified Eagle’s medium
ECL enhanced chemiluminescence
ECM extracellular matrix
ELISA enzyme-linked immunosorbent assay
ERK extracellular signal-regulated kinase
FBS fetal bovine serum
hnRNP heterogeneous nuclear ribonucleoprotein
HuR hypoxia-induced stability factor
MAPK mitogen-activated protein kinase
PAIP2 poly(A)-binding protein-interacting protein 2
RQ-PCR real time RT-PCR
RRM RNA recognition motif
RS domain domain rich in alternating serine and
arginine residues
SAPK/JNK stress-activated protein kinase/
Jun-amino-terminal kinase
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel
electrophoresis
siRNA small interfering RNA
SRp serine/arginine-rich protein
UTR untranslated region
VEGF vascular endothelial growth factor
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Angiogenesis is important for the expansion of solid and
hematologic cancers. In response to metabolic changes
occurring within the tumor microenvironment, such as
increased hypoxia and acidosis [1], a cascade of events
takes place, resulting in the production of angiogenic
“promoters” (stimulators) and a decrease in angiogenesis
inhibitors [2–4]. One of the best known angiogenic
stimulators, produced by most tumors, is the vascular
endothelial growth factor (VEGF-A).
The VEGF-A gene undergoes alternative splicing be-
tween exons 5 and 8 (Fig. 1)[ 5]. This mechanism results in
the predominant production of four isoforms, which differ
in molecular weight, and are thus known as VEGF121, 165,
189, and 145. VEGF165 is the predominant secreted
isoform, produced by most cell types (and most tumors),
and although it is a diffusible protein, a significant fraction
binds to the extracellular matrix (ECM). In contrast,
VEGF121 is a freely diffusible isoform that does not bind
to heparin, while VEGF189 binds strongly to heparin and
therefore is completely sequestered in the ECM. The
isoform 145 of VEGF is observed preferentially in
carcinomas of the female reproductive system [6]. The
importance of selective VEGF isoform secretion by tumors
has been demonstrated [7]. In detail, tumors that secrete
predominantly the VEGF121 isoform have increased dilated
and peripheral blood vessels, while tumors overexpressing
VEGF189, had highly branched and internal neo-vascula-
ture [8]. More recently, increased ratio of VEGF121 versus
the 165 or 189 isoforms was shown to be critical for the
angiogenic phenotype of prostate cancers [9].
VEGF-A is produced by cells under stress, such as during
hypoxia, resulting in tissue angiogenesis and oxygenation,
although the molecular mechanisms regulating VEGF pro-
duction in response to microenvironmental stimuli other than
hypoxia, such as acidosis, are still poorly characterized [10].
Alternative splicing is a major mechanism for modulat-
ing the expression of cellular and viral genes and enables a
single gene to increase its coding capacity. The VEGF
isoforms mentioned above represent one family of proteins
whose expression may be regulated by alternative splicing.
The family of SR (serine/arginine-rich) proteins has been
implicated in splicing; they are characterized by an RNA
recognition motif (RRM) and a C-terminal domain rich in
alternating serine and arginine residues (the RS domain)
[11]. The RRMs determine RNA binding specificity,
whereas the RS domain mediates protein-protein interac-
tions that are thought to be essential for the recruitment of
the splicing apparatus and for the splice site pairing.
In the present report, we studied the influence of
microenvironment cues that could affect the VEGF-A gene
splicing pattern, and determined the molecular mechanisms
involved.
Results
Microenvironment Changes Affect VEGF Alternative
Splicing Pattern
We investigated how changes in the microenvironment
might affect the pattern of VEGF alternative splicing
(Fig. 1), using endometrial carcinoma cells as a model
Fig. 1 VEGF isoforms that result from pre-mRNA alternative
splicing. These isoforms differ in the presence or absence of exons 6
and 7 that codes for heparin-binding domains and in the presence of
exon 8a or 8b that induce antagonist effects of VEGF. The localization
of the probes and primers used to amplify the different isoforms of
VEGF are indicated by a line or an arrow, respectively. The lines and
arrows in blue represent the probes and primers used to amplify either
VEGF165+VEGF165b or VEGF189+VEGF189b
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purpose, we induced changes in the culture medium (by
exposing the cells to acidic pH, progesterone, β-estradiol,
glucose and cobalt chloride, to mimic for hypoxia), and
quantified the ratio of VEGF isoforms by real time RT-PCR
(RQ-PCR). As expected, hypoxia significantly increased
VEGF production, as did acidosis (Fig. 2a,b and Supple-
mentary Fig. 1). However, a more evident shift in the pattern
of VEGF isoforms produced, occurred in samples subjected
to lower pH. A pH 5.5 induced a preferential VEGF121
increase (p<0.001), suggesting it modulated the mechanisms
involved in alternative splicing.
The VEGFxxxb isoforms, previously shown to be
involved in the regulation of tumor angiogenesis [12], were
expressed at very low levels by the cell line used in our
studies. Notably, in this study VEGFxxxb isoforms did not
accompany the variations observed in VEGFxxx isoforms
(VEGF165b and VEGF189b did not differ significantly from
control to pH 5.5 conditions, p>0.05). Therefore we
concluded that the modifications in VEGF alternative
splicing observed in low pH, did not involve the VEGFxxxb
alternative transcripts (Fig. 3).
The shift in VEGF isoform ratio occurred within 6 h of
pH 5.5, but the greatest difference was seen after 8 h of
stimulation (Fig. 4a).
VEGF Isoform Shift in Acidic pH is Accompanied
by p38/MAPK Activation
Since acidic pH induced a shift in isoform production by
RL95 cells, next we sought to define the signaling pathways
that might be involved in this effect.
As shown in Fig. 4b, 8 h in acidic pH induced the
activation of the stress signaling pathways p38 MAPK
(p<0.05) and SAPK/JNK, while ERK and Akt remained
unchanged. In vitro blockade of the two signaling pathways
using specific inhibitors demonstrated that cells cultured in
the presence of the p38 pathway inhibitor (SB202190) did
not respond to the acidic pH (Fig. 4c). Under these
conditions the shift in VEGF isoform production was not
observed (VEGF121 was not significantly different from all
the other isoforms, p>0.05), while the SAPK/JNK inhibitor
SP600125 had little effect (VEGF121 vs VEGF165, p<
0.001, as observed in pH 5.5 condition). These data indicate
that the p38 stress signaling pathway may be involved in
the effects of acidic pH that result in modulation of the
VEGF alternative splicing pattern.
SR Proteins Could be Involved in the Regulation of VEGF
Isoforms
SR proteins have been described to be involved in the
control of constitutive and alternative splicing of genes
[11]. To evaluate which SR proteins could be activated by
the p38 stress signaling pathway and involved in VEGF
isoform shift in acidic conditions, the modulation of SR
proteins was investigated.
Using an antibody against phosphorylated-SR proteins,
we verified that the up-regulation of these proteins
correlates with activation of the p38 signaling pathway
and the shift in VEGF isoform production (Fig. 5a). Since
these proteins can shuttle between the nucleus and
cytoplasm we confirmed that the majority of these proteins
were localized at the nucleus in pH 5.5 (data not shown)
and could be acting as splicing regulators.
By real time RT-PCR we quantified the mRNA of
different SR proteins (SF2/ASF, SRp20 and SRp40) and
observed that pH 5.5 induced a significant up-regulation
(p<0.05) of SRp20 that could be partially inhibited in the
presence of SB202190, the p38 MAPK inhibitor (Fig. 5b).
This result indicates that p38 MAPK was not acting at the
SR proteins mRNA levels and could have a role at mRNA
translation or SR proteins activation (protein phosphoryla-
Fig. 2 VEGF isoforms expression pattern by RL95 cells in response
to changes in the microenvironment. By real time RT-PCR (a) and
ELISA (b), we can see an increase in VEGF production in acidic and
hypoxic (mimicked by CoCl2) conditions. A shift in the VEGF
isoforms splicing pattern is more evident at pH 5.5 where VEGF121
expression is significantly different from all other isoforms (p<0.001).
In hypoxic conditions VEGF121 is also significantly different from
VEGF145 and 189 (p<0.001) and from VEGF165 (p<0.05). In a the
level of each isoform in different conditions is represented relatively to
control conditions (which is considered equal to 1). In graph a n=10
and in graph b n=3
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VEGF alternative splicing we used siRNA against each SR
protein and tested the effect in the pattern of VEGF isoform
production. siRNA against SF2/ASF, SRp20 or SRp40
reduced the production of the VEGF121 observed in pH 5.5
(in fact, the VEGF isoforms pattern in these conditions is
equal to the control), suggesting that not only we have
prevented VEGF expression but also have prevented the
shift in the VEGF isoforms pattern (p>0.05; Fig. 6b). Thus,
SF2/ASF, SRp20 and SRp40 may have a role at the VEGF
alternative splicing process. These three proteins might also
have a role in the alternative slicing of a VEGF regulator
since by its down-regulation we affected the VEGF
expression.
Since these proteins have RNA recognition motifs, we
used bioinformatics software to search putative binding
Fig. 3 Discrimination between
VEGFxxx and VEGFxxxb iso-
forms expression in acidic pH.
In pH 5.5 there was a significant
increase in VEGF165 (p<0.001)
and 189 (p<0.01) but the ex-
pression of VEGF165b (p<
0.001) and 189b (p<0.001) is
too low when compared respec-
tively to the VEGF165 and 189
and do not change in acidic
conditions (p>0.05 for both
isoforms). The graphs represent
the mean of three experiments
Fig. 4 a Correlation between VEGF isoforms pattern inversion and
the activation of stress signaling pathways in acidic conditions. After
8 h of pH 5.5 stimulation, the changes in VEGF isoform splicing
pattern are more pronounced. b As shown by western blotting and
densitometry quantification, at this time point, from the several
signaling pathways analyzed, only the p38 MAPK (p<0.05) and the
SAPK/JNK stress pathways were activated. c SB202190 and
SP600125 were used to inhibit p38 MAPK and SAPK/JNK stress
pathways, respectively. In the presence of the p38 inhibitor, low pH
failed to induce a shift in VEGF splicing pattern (all VEGF isoforrms
are similar, p>0.05), while the SAPK/JNK inhibitor could not prevent
the shift in VEGF isoforms (VEGF121 is significantly different from
VEGF165, p<0.001). Graphs a and c represent the mean of three
experiments and the blot was repeated three times
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and SRp40. This approach showed that SRp20 and SRp40
do not have putative binding sites at the exons of VEGF
that are involved in alternative splicing, but SF2/ASF
has putative binding sites at exons 5, 7 and 8 of VEGF.
Therefore, we may speculate that the SF2/ASF protein may
act on alternative splicing of VEGF by binding directly to
the VEGF sequence and in contrary, the SRp20 and SRp40
could be exon-binding independent by recruiting splicing
factors through its serine/arginine rich domain (SR proteins
property already described by Wu and Maniatis in 1993)
[13].
Since SR proteins are large families of proteins involved
in the global mechanisms of alternative splicing, a more
detailed study must be done in order to identify other SR or
hnRNP (SR proteins antagonists, heterogeneous nuclear
ribonucleoproteins) proteins that may regulate the VEGF
isoforms pattern in acidic conditions.
Fig. 6 a Effect of SR proteins down-regulation in VEGF alternative
splicing in acidic conditions. siRNA for SF2/ASF, SRp20 and SRp40
(performed in triplicate) were used and its efficacy was demonstrated
by real time RT-PCR. b Using siRNA for SF2/ASF, SRp20 and
SRp40, there was no shift in the VEGF isoforms pattern observed in
acidic conditions, since all isoforms were similar to each other (p>
0.05) and to the control (p>0.05)
Fig. 5 a SR proteins involved
in the control of the VEGF
splicing pattern. Most SR pro-
teins were up-regulated in acidic
conditions both after 6 and 8 h
of exposure. b Expression of the
SR protein SRp20, in RL95,
increased significantly (p<0.05)
in acidic conditions and was
only partially inhibited in the
presence of the p38 MAPK
inhibitor SB202190. In graph b
the error bars represent the
standard deviation of three in-
dependent experiments
Microenvironment regulates VEGF splicing 135Taken together, we propose a model where the activation
of the p38 stress signaling pathway in response to a
microenvironment signal (such as a decrease in pH levels)
accompanies a change in VEGF alternative splicing and an
increase in alternative splicing factors phosphorylation (SR
proteins; see our proposed model in Fig. 7).
Discussion
Angiogenesis is an essential property of all tumors,
allowing tumor expansion and contributing towards metas-
tasis dissemination. Since it is a common feature of most
malignancies, the importance of angiogenesis as a thera-
peutic target has been well documented [14]. Regarding the
molecular signals that control the tumor angiogenesis
process, the increased production of pro-angiogenic factors
by most tumors has received great attention, most notably
the recognition of VEGF-A as a key angiogenic factor for
the majority of tumors [15]. VEGF-A has several isoforms,
whose importance in the context of tumor angiogenesis has
already been addressed. Although VEGF-A isoforms can
bind differently to the ECM, they have also been attributed
with different capacity to modulate the tumor vasculature
[8, 16]. In detail, VEGF 121 has been described as more
angiogenic and tumorigenic in breast [17] and prostate [9]
cancer and also to specifically improve oxygenation in
experimental breast tumors [18], while VEGF189 contributes
to the establishment of distant metastasis of pulmonary
adenocarcinoma [19]. Given the lack of mechanistic infor-
mation concerning the regulation of the VEGF alternative
splicing process, in the present report we hypothesized that
cues in the tumor microenvironment might selectively affect
the VEGF splicing pattern, and studied the mechanisms
involved in this effect.
Tumor microenvironment signals such as hypoxia and
acidosis have been suggested to play a major role in the
control of VEGF-A production, and consequently in
modulation of angiogenesis [20]. In fact, hypoxia and
acidosis are common features of the majority of solid and
hematologic malignancies, perhaps as a consequence of the
tumor metabolic needs, or as a consequence of an altered
(pro-malignant) microenvironment. Importantly, the extra-
cellular pH has been recognized as an inducer of VEGF,
and also to regulate the VEGF interactions with different
cells and with components of the extracellular matrix [21].
In the present study, acidosis consistently affected the
VEGF alternative splicing pattern produced by endometrial
cancer cells (used as a model); this correlated to a shift in
the usual VEGF isoform expression pattern, resulting in an
significant increase in the VEGF121, that was not accom-
panied by the other VEGF isoforms.
The involvement of signaling pathways and splicing
machinery had not been studied in the context of VEGF
alternative splicing. In our report, we reveal the involve-
ment of p38 and possible members of the SR protein family
in this mechanism. We now intend to perform a more
detailed characterization of the splicing machinery involved
in the VEGF alternative splicing in tumor cells exposed to
different microenvironment cues.
Importantly, in addition to alternative splicing regulation,
the levels of each isoform of VEGF can also be modulated
Fig. 7 Proposed model. When
endometrial cancer cells are ex-
posed to acidic medium the p38
MAPK signaling pathway is
activated and an increase in SR
proteins phosphorylation that
will eventually regulate the
VEGF alternative splicing takes
place. In acidosis, not only
VEGF expression is increased
but also a modification of the
alternative splicing occurs,
where an increase in the pro-
portion of VEGF121 versus
VEGF145, 165, and 189 is
observed
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that anisomycin (a strong activator of stress-activated
protein kinases, SAPKs) increased VEGF mRNA stabiliza-
tion through the activation of p38 kinase and JNK. This
protein induce the recruitment of HuR (one of the Hu
family proteins) and PAIP2 (poly(A)-binding protein-
interacting protein 2) to the AU-rich elements (AREs) in
the 3′-untranslated region (3′ UTR) of VEGF mRNA [23].
Since the ARE sequence at the 3′ UTR of the VEGF
mRNA is present in all the isoforms, there is a possibility
that all isoforms have the same stability and that the
differences observed in VEGF isoforms ratio were not due
to a difference in mRNA stability. In fact, a study that
correlates the VEGF144 up-regulation with glucose starva-
tion, suggest that other mechanism apart mRNA stability
must also exist to explain the dramatic increase observed
(the increased stability observed for this isoform was
approximately threefold but the increase in mRNA was
~400-fold) [24]. Nevertheless, more studies have to be done
to address this important question.
Additionally, the p38 pathway, which is an important
stress signaling pathway that have been described to control
VEGF at the mRNA expression [25] and stability level
[22], was also shown to act directly or indirectly in the
alternative splicing of this gene.
In conclusion, we postulate that changes of VEGF
isoforms observed in acidic conditions may represent the
adaptation of tumors to alterations in the microenviron-
ment, namely by activating angiogenic signaling pathways,
through different VEGF isoforms production.
Material and Methods
All reagents were obtained from Sigma, unless otherwise
stated.
Cell Lines and Cell Culture Conditions
The RL95 cell line was kindly provided by Professor Steve
Smith (currently Principal of the Faculty of Medicine,
Imperial College, London, UK). It was cultured in 50%
high glucose Dulbecco’s modified Eagle’sm e d i u m
(DMEM) medium (Sigma) and 50% nutrient mixture F-12
Ham (Sigma), supplemented with 10% FBS, 100 µg/ml of
streptomycin sulfate, 100 U/ml of penicillin G sodium,
2m Mo fL-glutamine and 0.1 µg/ml of amphotericin B as
Fungizone. Cells were cultured at 37°C in a 5% CO2
atmosphere.
Upon reaching confluency, RL95 cells were submitted to
changes in pH (pH 5.5, to mimic for acidosis), oxygen,
glucose (100 mM) or hormones levels. To obtain an acidic
medium we used HCl and the pH 5.5 was confirmed before
and after the experiment using a pH electrode. To induce
hormonal changes and to mimic hypoxia, β-estradiol
(100 nM)/progesterone (1 µM) and cobalt chloride
(150 µM) [26] were used respectively.
To test the importance of the different signaling path-
ways in the regulation of VEGF alternative splicing, the
RL95 cell line was cultured in growth medium at pH 5.5
with or without the inhibitors of p38 MAPK (SB202190,
Sigma, 20 µM,) and SAPK/JNK (SP600125, Sigma,
20 µM) signaling pathways.
RNA Isolation and Real Time RT-PCR with TAQMAN
or Sybergreen
RNA was extracted by Trizol reagent (Invitrogen) and 2 µg
of total RNA was used to synthesize cDNA [27]. The
mRNA level of each VEGF isoform was measured by real
time RT-PCR (TAQMAN or Sybergreen) on the ABI
Prism® 7900HT Sequence Detection System (Applied
Biosystems) using specific primers and probes represented
Table 1 Primers and probes used in real time RT-PCR for VEGF isoforms
VEGF isoforms Probes (6-FAM-5′ → 3′-TAMRA) Primers (5′ → 3′)
121 ACAGCACAACAAATGTGAATG Forward CCAGCACATAGGAGAGATGAGCTT
CAGACCAAA Reverse CGGCTTGTCACATTTTTCTTGTC
145 AGAGCAAGACAAGAAAAAAAA Forward AATGTGAATGCAGACCAAAGAAAG
TCAGTTCGAGGAA Reverse CACATACGCTCCAGGACTTATACC
165+165b ACAGCACAACAAATGTGAATG Forward CCAGCACATAGGAGAGATGAGCTT
CAGACCAAA Reverse AGGCCCACAGGGATTTTCTT
189+189b AGAGCAAGACAAGAAAAAAAA Forward AATGTGAATGCAGACCAAAGAAAG
TCAGTTCGAGGAA Reverse AGGGAACGCTCCAGGACTTATA
165b – Forward AAGAAAATCCCTGTGGGCCTT
Reverse TGGTGAGAGATCTGCAAGTACGTT
189b – Forward CTGGAGCGTTCCCTGTGG
Reverse TGGTGAGAGATCTGCAAGTACGTT
Microenvironment regulates VEGF splicing 137in Fig. 1 and Table 1. Expression of different SR proteins
was analyzed with Sybergreen with specific primers (SF2/
ASF: forward—5′-GAA CAA CGATTG CCG CAT CT-3′,
reverse—5′-AAT CAT AGC CGT CGC GAC C-3′; SRp20:
forward—5′-GCA TCG TGA TTC CTG TCC ATT-3′,
reverse—5′-GTT CTT CCA TCT AGC TCT CGG ACT-
3′; SRp40: forward—5′-CTG TCG GGT ATT CAT CGG
GA-3′, reverse—5′-ACG GTC AGA GTA TCG TCC TCT
ACC T-3′). Real time PCR program consisted of an initial
denaturation step at 95°C for 10 min followed by 40 cycles
at 95°C for 15 s and at 60°C for 1 min. The housekeeping
gene used to normalize the samples in TAQMAN assay was
the 18S (Human 18S rRNA—20×, Applied Biosystems).
For Sybergreen, the BCR gene was used (forward—5′-
GAG CGT GCA GAG TGG AGG GAG AAC A-3′;
reverse—5′-CAC AGT ATC CTC AGG GTC TGG GA-3′).
The relative expression of each sample was calculated
with respect to a standard calibration curve that represents a
serial dilution of a cDNA. Each sample was analyzed in
triplicate and each PCR experiment included at least one
non-template control well.
ELISA, Protein Extraction and Western Blotting
Culture supernatants from RL95 in different conditions
were collected and used to measure human VEGF by
ELISA (Oncogene Research Products) under conditions
described by the supplier.
To extract total proteins the pellets were suspended in a
buffer containing 1% NP40, 10% glycerol, 50 mM Tris–
HCl pH 7.5, 0.1% sodic azid and 150 mM NaCl,
supplemented with protease and phosphatase inhibitors.
After 30 min in ice, lysates were centrifuged for 15 min at
4°C and 12,000 rpm.
Equal proteins amount were separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to nitrocellulose membranes. Blots were
incubated overnight with an antibody against phosphorilated
SR proteins [mouse anti-SR proteins 1 (H4) from Zymed] at
a concentration of 10 µg/ml. Antibodies against P-AKT, P-
ERK, P-JNK (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), P-p38 (cell signaling) and actin (Sigma) were used at
final concentration of 100 ng/ml, 400 ng/ml, and a dilution
of 1:500, 1:1,000 and 1:2,000 respectively. Western blotting
was performed following conventional protocols. Blots were
revealed with the ECL (Amersham) system, according to
manufacturers instructions. The hybridizing signals were
quantified with ImageJ software.
siRNA for SR proteins
One day before transfection, 1×10
5 RL95 cells were plated
in 500 µl of growth medium without antibiotics in a 24-
well culture vessel. Fifty picomoles of each siRNA (SFRS1
for SF2/ASF; SFRS3 for SRp20 and SFRS5 for SRp40
from Ambiom Company) were used. The RNA and 1 µl of
Lipofectamine 2000 (Invitrogen) were diluted separately in
50 µl of Opti-MEM I reduced serum medium. After 5 min
of incubation, the two dilutions were combined and
incubated for 20 min at room temperature. This mixture
was then added to the cells following an incubation of 6 h
at 37°C and 5% CO2. After transfection, the medium was
replaced. The effect of transfection was assessed after 72 h.
Bioinformatics Approach/Program
The splicing rainbow (Morais & Valcarcel EMBL 2002 at
http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8)b i o i n f o r -
matics software was used to find putative binding sites for
SF2/ASF, SRp20 and SRp40 proteins in the VEGF
sequence. From the list of binding sites received after the
VEGF sequence analysis we only choose as putative
binding sites the sequences with higher scores (S) that
were in exons. In detail, a sequence was considered a
putative binding site for SRp20, and SF2/ASF if S>6 and
for SRp40 if S>5.
Statistical Analysis
Results are expressed as mean ± standard deviation. Data
were analyzed using the unpaired two-tailed Student’s t
test or the one-way ANOVA with post Tukey test. p values
of <0.05 were considered significant.
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